Stomach Neoplasm Clinical Trial
— VNPOfficial title:
Incidence of Dumping Syndrome After Laparoscopic Vagus Nerve-preserving Distal Gastrectomy for Early Gastric Cancer
NCT number | NCT03880747 |
Other study ID # | SNUBHGS_VNP |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 9, 2017 |
Est. completion date | August 20, 2020 |
Verified date | March 2021 |
Source | Seoul National University Bundang Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
There is no consensus on what type of function-preserving gastrectomy can provide the best patient quality of life (QOL). This study aims to evaluate the incidence of dumping syndrome after vagus nerve-preserving distal gastrectomy (VPNDG).
Status | Completed |
Enrollment | 100 |
Est. completion date | August 20, 2020 |
Est. primary completion date | August 19, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients diagnosed with early gastric cancer in the distal 2/3rd of the stomach planned to undergo laparoscopic vagus nerve-preserving distal gastrectomy Exclusion Criteria: - Sacrificed vagus nerve - Anastomosis other than Roux-en Y gastrojejunostomy or uncut Roux-en Y gastrojejunostomy - conversion to an open procedure - combined resection of other organs |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | Gyeonggi-do |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Bundang Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Operative time | Time of operation | Immediately after operation | |
Other | Estimated blood loss | Blood loss during operation | Immediately after operation | |
Other | Time to first flatus | Postoperative day to first flatus | Within 1 week | |
Other | Hospital stay | Total hospital stay | Within 1 week | |
Primary | Dumping syndrome | Sigstad score of equal or more than 7 | 1 year | |
Secondary | EORTC C-30/STO22 | Quality of life surveys | 3 months, 6 months, 1 year | |
Secondary | Postoperative complication | incidence of postoperative complication | 3 months, 6 months, 1 year | |
Secondary | Incidence of gallstones | Found in follow-up CT or ultrasound | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03313700 -
Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer
|
N/A | |
Recruiting |
NCT05645198 -
The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy
|
Phase 4 | |
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT00144378 -
Irinotecan Versus Only Best Supportive Care for Gastric Cancer
|
Phase 3 | |
Completed |
NCT00935779 -
Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer
|
N/A | |
Completed |
NCT00290966 -
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT03348150 -
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
|
Phase 3 | |
Not yet recruiting |
NCT06085677 -
The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
|
||
Recruiting |
NCT02969122 -
Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor
|
N/A | |
Completed |
NCT01482299 -
RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression
|
Phase 2 | |
Active, not recruiting |
NCT03760822 -
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
|
Phase 2 | |
Recruiting |
NCT00509964 -
Second-Line Irinotecan vs. ILF for AGC
|
Phase 2 | |
Completed |
NCT04889859 -
Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy
|
N/A | |
Completed |
NCT03071237 -
The Origin of Infrapyloric Artery
|
||
Recruiting |
NCT05184803 -
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
|
Phase 2 | |
Completed |
NCT05714878 -
Multimodal Prehabilitation for Resectable Gastric Cancer
|
N/A | |
Completed |
NCT00142038 -
Docetaxel and Capecitabine in Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04056260 -
ICG-NIR Guided Lymph Node Dissection in Gastric Cancer
|
N/A | |
Recruiting |
NCT03065257 -
Endoscopic Resection Multicenter Registry
|
N/A | |
Recruiting |
NCT04744649 -
Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
|
Phase 2 |